Igor Vivanco, PhD, King’s College London, London, UK, discusses the possibility of oncogene addition in glioblastomas. Many targeted therapies have difficulty crossing the blood-brain barrier, where various EFGR inhibitors such as lapatinib can reach the brain but at insufficient doses. Identifying this issue has been delayed due to the intratumoral concentrations of these medications not being measured in clinical trials. Resistance to the aforementioned therapies can additionally arise due to suppression of certain genes such as the PTEN gene. This interview took place at the British Neuro-Oncology Society (BNOS) Annual Meeting 2022.
Dr Vivanco reports has received consulting honoraria from Abbvie and Aadi, as well as research funding from Roche, Genmab, and Basilea.